Yubin Kang, MD

Publications

Theivanthiran, Balamayoora, Kathy S. Evans, Nicholas C. DeVito, Michael Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April Ks Salama, et al. “A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.” J Clin Invest 130, no. 5 (May 1, 2020): 2570–86. https://doi.org/10.1172/JCI133055.

PMID
32017708
Full Text

Huang, Qiang, Malkiel A. Cohen, Fernando C. Alsina, Garth Devlin, Aliesha Garrett, Jennifer McKey, Patrick Havlik, et al. “Intravital imaging of mouse embryos.” Science 368, no. 6487 (April 10, 2020): 181–86. https://doi.org/10.1126/science.aba0210.

PMID
32273467
Full Text

Dupuis, Megan M., Barry Paul, Gavin Loitsch, Parker Mathews, Daniel Feinberg, Ian Barak, Zhiguo Li, Sascha A. Tuchman, and Yubin Kang. “Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.” Jco Oncology Practice, April 2, 2020, JOP1900517. https://doi.org/10.1200/jop.19.00517.

PMID
32240071
Full Text

Fan, Shengjun, Trevor Price, Wei Huang, Michelle Plue, Jonathan Warren, Pasupathi Sundaramoorthy, Barry Paul, et al. “PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ Pathway.” Adv Sci (Weinh) 7, no. 5 (March 2020): 1900860. https://doi.org/10.1002/advs.201900860.

PMID
32154065
Full Text

Theivanthiran, Balamayooran, Kathy Evans, Nicholas DeVito, Michael Plebanek, Michael Sturdivant, Alisha Holtzhausen, Luke Wachsmuth, et al. “A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.

Scholars@Duke

Kumar, Shaji K., Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, et al. “NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.” J Natl Compr Canc Netw 17, no. 10 (October 1, 2019): 1154–65. https://doi.org/10.6004/jnccn.2019.0049.

PMID
31590151
Full Text

Cornell, Robert, Hari Parameswaran, Shijie Tang, Alyssa Barnstead, Noa Biran, Natalie Callander, Ajai Chari, et al. “Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM).” In Clinical Lymphoma Myeloma and Leukemia, 19:e115–16. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.191.

Full Text

Gandhi, Ujjawal H., Robert F. Cornell, Arjun Lakshman, Zhubin J. Gahvari, Elizabeth McGehee, Megan H. Jagosky, Ridhi Gupta, et al. “Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.” Leukemia 33, no. 9 (September 2019): 2266–75. https://doi.org/10.1038/s41375-019-0435-7.

PMID
30858549
Full Text

Paul, Barry, Gavin Loitsch, Daniel Feinberg, Ian Barak, Zhiguo Li, Endi Wang, Yue Zhao, Megan Dupuis, and Yubin Kang. “The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Scholars@Duke

Pages